US Bancorp DE Cuts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

US Bancorp DE trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 33.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,148 shares of the medical research company's stock after selling 4,578 shares during the quarter. US Bancorp DE's holdings in Charles River Laboratories International were worth $1,689,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares during the period. Assetmark Inc. lifted its position in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares during the period. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after buying an additional 65 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International during the third quarter worth about $59,000. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International during the fourth quarter worth about $56,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have commented on the company. TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a report on Monday, March 3rd. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, UBS Group reaffirmed a "neutral" rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and a consensus price target of $198.36.

Charles River Laboratories International Trading Up 4.1 %

Shares of CRL traded up $6.93 during trading hours on Friday, reaching $176.20. The stock had a trading volume of 1,169,106 shares, compared to its average volume of 699,906. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $274.77. The firm has a 50-day moving average of $169.15 and a 200 day moving average of $185.76. The company has a market cap of $9.01 billion, a P/E ratio of 1,174.68, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.46 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James C. Foster bought 6,075 shares of the stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).